-
Breast Cancer: Targets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women
Original Research
(4712) Total Article Views
Authors: Patil AV, Bhamre RS, Singhai R, Tayade MB, Patil VW
Published Date April 2011
Volume 2011:3 Pages 27 - 33
DOI: http://dx.doi.org/10.2147/BCTT.S17892
Amit V Patil1, Rahul S Bhamre2, Rajeev Singhai3, Mukund B Tayade4, Vinayak W Patil31Department of General Surgery, Government Medical College, Miraj, Maharashtra, India; 2Department of General Surgery, DY Patil Hospital and Research Centre, Nerul, Navi Mumbai, India; 3Department of Biochemistry, Grant Medical College and Sir JJ Group of Hospitals Mumbai, India; 4Department of General Surgery, Grant Medical College and Sir JJ Group of Hospitals Mumbai, India
Objective: To determine the expressions and relationship between estrogen receptors (ERs) and progesterone receptors (PgRs) in breast cancer in Indian women.
Participants: Surgically removed breast cancer tissues were collected from Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India, taking (n = 300) cases of infiltrating duct cancer of Indian women after radical mastectomy and lumpectomy; the age- and menopausal-related subgroups satisfied this requirement.
Measurements: Statistical significance was calculated by the likelihood ratio test; relative risk served to check for significant differences. Relapse-free interval probabilities were calculated according to Kaplan and Meier, with Cox–Mantel test comparing survival functions and P values.
Results: We observed that only in middle-aged postmenopausal patients bearing pT2 tumors were ER and PgR receptors shown to have a prognostic significance with the lowest tested cutoff value being 5 fmol/mg.
Conclusion: Immunohistochemistry analysis has been shown to be a prognostic factor for patients with breast cancer; the major aim of determining the ER receptor status is to assess predictive response to hormonal therapy.
Keywords: prognostic cancer tissue biomarkers, immunohistochemistry, hormone receptors, steroid receptors
This paper has been retracted.
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Other articles by Dr Rajeev Singhai
Readers of this article also read:
-
Call For Submissions
Submit Original Research Article, Review, Case Report, or Rapid Communication in Breast Cancer: Targets and Therapy
- Epigenomics in cancer management
- The bradykinin B2 receptor induces multiple cellular responses leading to the proliferation of human renal carcinoma cell lines
- Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation
- Integrative systems of genomic risk markers for cancer and other diseases: future of predictive medicine




